Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have discovered a ...

The Interleukin-2 (IL-2) market is witnessing rapid growth due to advancements in cancer immunotherapy and autoimmune disease management. IL-2, a vital cytokine, promotes T-cell growth, with therapies ...

The global brain cancer treatment market is rapidly evolving, driven by the increasing incidence of brain cancer and advancements in medical technology focusing on personalized medicine. With ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

A new antibody treatment prevents cholesterol buildup in heart mitochondria and restores energy production, offering hope for ...

ELIAS Cancer Immunotherapy was combined with chemotherapy in a study with results presented at the 2025 ACVIM Forum ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.

Scientists uncover surprising immune response that helps tumors grow, revealing new strategies to improve treatment ...

It’s a revolution in cancer treatment, and it’s available right here in Houston. Dr. Philip Salem, oncologist and founder of Salem Oncology, recently stopped by Houston Life, alongside his patient, ...

EGFR inhibitors such as Erbitux and Gilotrif show potential in laboratory and mouse studies in treating melanoma with a ...

Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma.